All In Biotech

Drug Trial Radar · NCT06677996

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

A Phase 1, Open-Label, Fixed Sequence, 1-way Crossover Study Examining the Effect of Itraconazole on the Pharmacokinetics, Safety and Tolerability After Varegacestat Single Dose Administration to Healthy Participants

Last checked: Nov 20, 2026Latest source record: May 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Nov 11, 2024

Primary completion

Dec 30, 2024

Study completion May 7, 2025

Sponsor

Lead sponsor
Immunome, Inc.Industry
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.

Conditions

  • Healthy Volunteer

Interventions

  • varegacestatDrug

    Experimental intervention

  • Itraconazole (200 mg)Drug

    Intervention to evaluate DDI with experimental intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of itraconazole on the PK of varegacestat in healthy participants.Time frame: Up to 5 weeks
  2. Effect of itraconazole on the PK of varegacestat in healthy participants.Time frame: Up to 5 weeks
  3. Effect of itraconazole on the PK of varegacestat in healthy participants.Time frame: Up to 5 weeks
  4. Effect of itraconazole on the PK of varegacestat in healthy participants.Time frame: Up to 5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.